SCHEMBL3835299

SCHEMBL3835299

CCN1CCCC1CN(Cc1ccc(C(=O)Nc2ccccc2NC(=O)OC(C)(C)C)cc1)C(=O)NC1=COC=C(C2=CC=CCC2)O1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.37
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
GAA P10253 2/20 0.37
HPGD P15428 2/20 0.37
POLB P06746 1/20 0.37
ALOX12 P18054 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 6/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
KDM1A O60341 1/20 0.34
CHRM3 P20309 2/20 0.33
MCHR1 Q99705 2/20 0.33
MCHR2 Q969V1 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2476680 0.89 HDAC1 (0.37) ALDH1A1MEN1KMT2AGAAHPGD
SCHEMBL4393285 0.88 CHRM3 (0.38) KDM1ACHRM3DRD1HRH2HTR2A
SCHEMBL10476399 0.88 ALDH1A1 (0.32) ALDH1A1MEN1KMT2AGAAHPGD
SCHEMBL3830936 0.84 HDAC1 (0.38) KDM1AHDAC3HDAC1HDAC2NCOR2
SCHEMBL3829607 0.84 HDAC1 (0.38) KDM1AHDAC3HDAC1HDAC2NCOR2
SCHEMBL3835556 0.84 KDM1A (0.39) ALDH1A1KDM4ELMNAKDM1AMCHR1
SCHEMBL3835238 0.83 HDAC1 (0.35) MAPTKDM1AHDAC3HDAC1HDAC2
SCHEMBL3835728 0.83 KDM1A (0.36) ALDH1A1MEN1KMT2AGAAHPGD
SCHEMBL3834059 0.83 KDM1A (0.38) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL3835046 0.83 KDM1A (0.38) ALDH1A1HPGDKDM4ELMNAKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 ALDH1A1 1040/4885MEN1 4006/4885KMT2A 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.